Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

kidney · Mechanism Report

Do an undetectable UACR and optimal SDMA provide reassuring kidney context without measuring TMAO clearance?

An undetectable UACR and non-elevated SDMA are reassuring kidney signals, but they do not directly measure TMAO clearance.

PlausibleSeptember 16, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

An undetectable urine albumin-to-creatinine ratio and optimal symmetric dimethylarginine provide reassuring kidney context, although neither directly measures trimethylamine N-oxide clearance.

laying out figure…
1 of 5 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says these two lab findings offer favorable kidney context by pointing to no detectable albuminuria and an indirect signal of filtration. The conclusion frames them as complementary but limited markers: they can suggest reassuring renal status, yet they cannot confirm TMAO-specific elimination, which requires direct timed urine and plasma testing.

Verified conclusion

A 52-year-old man with an undetectable UACR and laboratory-appropriate non-elevated SDMA has favorable—but targeted—renal context. These measures address albuminuria and indirectly filtration, not TMAO-specific elimination.

Kidney context

  • Undetectable UACR is strongly reassuring for absence of clinically significant albuminuria and falls within KDIGO A1 (<30 mg/g). It supports intact glomerular permeability on the tested sample.
  • This does not establish globally normal kidney function: CKD can occur with UACR <30 mg/g when eGFR is persistently <60 mL/min/1.73 m² or other kidney-damage markers are present. Non-albuminuric vascular, ischemic, tubulointerstitial, or fibrotic disease may also reduce filtration without albumin leakage.
  • SDMA is a plausible adjunctive filtration signal. It is predominantly renally cleared and correlated strongly with measured GFR in one adult comparison (r = −0.84). However, “optimal” is assay-specific (reported reference ranges include ~0.32–0.65 µmol/L), and SDMA is not a KDIGO-recommended standalone marker for CKD diagnosis or staging.

TMAO clearance and mechanism

  • Neither UACR nor SDMA directly quantifies TMAO elimination. SDMA’s correlation with TMAO is only moderate (approximately r = 0.42), insufficient to serve as a clearance surrogate.
  • Direct TMAO clearance requires paired plasma and timed urinary TMAO concentrations plus urine volume, typically quantified by LC-MS/MS. In human studies, TMAO clearance approximated measured GFR and mean fractional excretion was ~105%, supporting predominant filtration; yet loop diuretics and red-meat intake can reduce fractional excretion, indicating modifiable tubular handling.

Bottom line

  • Undetectable UACR and non-elevated SDMA are reassuring complementary kidney signals, but they cannot confirm normal TMAO clearance; eGFR/trajectory remain central for kidney context, while timed plasma–urine testing is needed for TMAO-specific clearance.

References

  1. [PDF] KDIGO-2024-CKD-Guideline.pdf — kdigo.org ↗
  2. Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders — pmc.ncbi.nlm.nih.gov ↗
  3. The future of diabetic kidney disease management: what to expect from the experimental studies? — academic.oup.com ↗
  4. Comparison of symmetric dimethylarginine with creatinine, ... — pubmed.ncbi.nlm.nih.gov ↗
  5. Comparison of symmetric dimethylarginine with creatinine, cystatin C and their eGFR equations as markers of kidney function — bevital.no ↗
  6. The new age of renal biomarkers – does SDMA solve all of our problems? — rvc-repository.worktribe.com ↗
  7. Associations of Plasma Trimethylamine N-Oxide–Related ... — pmc.ncbi.nlm.nih.gov ↗
  8. Simultaneous Measurement of Urinary Trimethylamine ... — pmc.ncbi.nlm.nih.gov ↗
  9. Table 2: — pmc.ncbi.nlm.nih.gov ↗
  10. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Supported7 sourcesUMOD rs12917707 variation influences kidney function and CKD risk.→